23 results
Thumbnail

D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study

Thumbnail

D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials

Thumbnail

D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy

Thumbnail

D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure

Thumbnail

D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents

Thumbnail

D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients

Thumbnail

D3.207 - Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece

Thumbnail

D3.209 - Subcutaneous Allergen Immunotherapy in Children: Frequency of Local and Systemic Adverse Reactions and Associated Risk Factors

Thumbnail

D3.308 - Kounis Syndrome: the allergic myocardial infarction

Thumbnail

D3.313 - Recurrent Anaphylaxis with Elevated Baseline Tryptase Revealing Hereditary Alpha-Tryptasemia with Mast Cell Activation

Thumbnail

D3.318 - Evaluation of Clinical Predictors and Serum Tryptase Levels in Systemic Mastocytosis

Thumbnail

D3.319 - Clinical Data of Drug Induced Anaphylaxis according to the standardized European Anaphylaxis Registry (NORA)

Thumbnail

D3.320 - Anaphylaxis by Chlorhexidine: A case series

Thumbnail

D3.321 - Cardiac arrest after Iodixanol: a case of non-IgE mediated mast cell activation

Thumbnail

D3.307 - Chlorhexidine-triggered anaphylaxis in a child with multisystem allergy and sickle cell disease: a diagnostic pitfall

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project